Solutions pushing the frontiers of science

The journey from target identification to pre-clinical phase is challenging, and often beyond the scope of a start-up. These highly driven, innovative companies are looking for a partner with the expertise and computational power to accelerate the drug discovery journey with them. Through a risk sharing approach, we support their research and co-develop promising biological targets for indications with high unmet needs.

Pharma companies may have specific needs or challenges that they require support with. It may be support in drug repurposing, either starting from the target or from a specific drug. Or support for new treatments identification. Or using the Exscalate platform to accelerate their pipeline development. Whatever the challenge, Exscalate’s computational power will offer a competitive advantage in their quest to develop drugs for ’undruggable’ targets.

For Academic Institutions, Independent Researchers and Regional Institutions/Governments. In drug discovery we are always racing against the clock. Novel treatments need to be discovered quickly and cost effectively. Exscalate uses its advanced capabilities to help with this whether it’s being part of a consortium of partners in rapidly developing candidate drugs for sudden health threats (such as Exscalate4Cov for Covid-19 or Antarex4Zika for the Zika virus) or supporting academic institutions and researchers in developing their research programs into new or existing drugs.